【正文】
liamson PR, Park BK, Deloukas P, Pirmohamed M. Genetic and environmental factors determining clinical outes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics. 2009。 19: 80012.[9]. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarintreated cohort supports genetic forecasting. Blood. 2009。 113: 78492.[10]. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009。 113: 392530.作者簡(jiǎn)介:第一作者:薛領(lǐng),男,碩士研究生,主要研究方向:臨床藥代動(dòng)力學(xué)及個(gè)體化給藥,電話:051267780467,Email:xueling726@通信作者:繆麗燕,女,教授,碩士研究生導(dǎo)師,主要研究方向:臨床藥代動(dòng)力學(xué)及個(gè)體化給藥,電話:051267780040,Email:miaolysuzhou@*通信作者:繆麗燕,江蘇省蘇州市十梓街188號(hào)蘇州大學(xué)附屬第一醫(yī)院臨床藥理研究室,215006 Tel: +86 512 67780040.Fax: +86 512 67780040.Email: miaolysuzhou@4 / 4